Vitamin D threshold to prevent aromatase inhibitor-related bone loss: The B-ABLE prospective cohort study

Daniel Prieto-Alhambra, Sonia Servitja, M. Kassim Javaid, Laia Garrigós, Nigel K. Arden, Cyrus Cooper, Joan Albanell, Ignasi Tusquets, Adolfo Diez-Perez, Xavier Nogues

Research output: Contribution to journalArticleResearchpeer-review

34 Citations (Scopus)


Aromatase inhibitor (AI)-related bone loss is associated with increased fracture rates. Vitamin D might play a role in minimising this effect. We hypothesised that 25-hydroxy-vitamin D concentrations [25(OH)D] after 3 months supplementation might relate to bone loss after 1 yearonAItherapy. Weconductedaprospectivecohort study from January 2006 to December 2011 of a consecutive sample of women initiating AI for early breast cancer who were ineligible for bisphosphonate therapy and stayed on treatment for 1 year (N = 232). Serum 25(OH)D was measured at baseline and 3 months, and lumbar spine (LS) bone mineral density at baseline and 1 year. Subjects were supplemented with daily calcium (1 g) and vitamin D 3 (800 IU) and additional oral 16,000 IU every 2 weeks if baseline 25(OH)D was <30 ng/ml. Linear regression models were fitted to adjust for potential confounders. After 1 year on AI therapy, 232 participants experienced a significant 1.68 % [95 % CI 1.15-2.20 %] bone loss at LS (0.017 g/cm 2 [0.012-0.024], P<0.0001). Higher 25(OH)D at 3 months protected against LS bone loss (-0.5 % per 10 ng/ml [95 % CI -0.7 to -0.3 %], adjusted P = 0.0001), and those who reached levels ≥C40 ng/ml had reduced bone loss by 1.70 % [95 % CI 0.4-3.0 %; adjusted P = 0.005] compared to those with low 25(OH)D levels (<30 ng/ml). We conclude that improved vitamin D status using supplementation is associated with attenuation of AI-associated bone loss. For this population, the current Institute of Medicine target recommendation of 20 ng/ml might be too low to ensure good bone health. © 2012 Springer Science+Business Media, LLC.
Original languageEnglish
Pages (from-to)1159-1167
JournalBreast Cancer Research and Treatment
Issue number3
Publication statusPublished - 1 Jun 2012


  • Aromatase inhibitors
  • Breast neoplasms
  • Epidemiology
  • Osteoporosis
  • Vitamin D


Dive into the research topics of 'Vitamin D threshold to prevent aromatase inhibitor-related bone loss: The B-ABLE prospective cohort study'. Together they form a unique fingerprint.

Cite this